NCT05951894 (sICAM-1) is a clinical trial in Obesity, sponsored by Universitas Airlangga.

Who is sponsoring NCT05951894?

NCT05951894 is sponsored by Universitas Airlangga.

What condition does NCT05951894 study?

NCT05951894 studies Obesity, Hypertension, Adolescent Obesity.

Is NCT05951894 still recruiting?

NCT05951894 is currently completed. Last updated 21 November 2023.

Last reviewed 2023-11-21 · How we verify

NCT05951894: sICAM-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Flow-mediated Arterial Dilatation, Hypertension, Endothelin-1 and sICAM-1 in Obese Adolescents

Completed Last updated 21 November 2023

What this trial tests

trial in Obesity in 70 participants. Completed in 31 October 2023.

Timeline

1 August 2023

Primary endpoint
31 October 2023

31 October 2023

Quick facts

Lead sponsor	Universitas Airlangga
Status	Completed
Study type	OBSERVATIONAL
Enrollment	70
Start date	1 August 2023
Primary completion	31 October 2023
Estimated completion	31 October 2023
Sites	1 location across Indonesia

Conditions studied

Obesity — all drugs for Obesity →
Hypertension — all drugs for Hypertension →
Adolescent Obesity — all drugs for Adolescent Obesity →

Sponsor

Universitas Airlangga — full company profile →

Who can join

Adults 13 to 18, any sex, with Obesity or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity in adolescents is associated with the development of cardiovascular disease and type 2 diabetes mellitus. In order to detect early development of cardiovascular disease, early detection of the endothelium of obese adolescents is needed. Endothelium dysfunction is an early stage of developing atherosclerosis, which can be a predictor of cardiovascular disease development in the future. Flow mediated dilatation (FMD) is a non-invasive method that can measure endothelium function and predict the risk of cardiovascular disease, which is not only able to measure artery diameter, but also provides function index of nitric oxide (NO) in the endothelium. FMD is negatively related to BMI. Meanwhile, Endothelin-1 (ET-1) is thought to play a role in the pathogenesis of insulin resistance, because when its levels increase, ET-1 can cause a condition of hyperinsulinemia. ET-1 was found to be high in patients with cardiovascular disorders, as well as in obese and diabetic subjects. Alternative methods for assessing endothelial function by measurement of biomarkers of activation and endothelial dysfunction such as soluble intercellular adhesion molecule-1 (sICAM-1). Levels of sICAM-1 have been found to be related positively to age, systolic and diastolic blood pressure, hypercholesterolemia, hypertriglyceridemia and inversely to estrogen. Furthermore, associations have been found between sICAM-1 and cardiovascular mortality in both healthy individuals and populations at high risk. The aim of the study was to evaluate FMD, concentrations of ET-1 and sICAM-1 in adolescents with a presence of obesity and hypertension and to compare these with controls (obesity and non hypertension), as well as to analyze the correlations between FMD, ET-1, sICAM-1 and blood pressure values.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Universitas Airlangga trials

Trials by the same sponsor.

NCT07418762 — Community-Based Program Integrating Nurse-Led Mind-Body Exercise and Nutrition for Frailty · NA · not yet recruiting
NCT07265856 — The Effect of a Comprehensive Dementia Education Program on Improving Attitudes Toward People Living With Dementia · NA · enrolling by invitation
NCT07238439 — Scenario-Driven Virtual Reality Game for Dementia Education Program · NA · enrolling by invitation
NCT06629844 — Enhancing Healthcare Students' Attitudes Toward Dementia Care Through Virtual Reality Education · NA · completed
NCT06160765 — The Efficacy of High Density Formula 1.5 kcal/ml or 1 kcal/ml On Catch Up Growth In Growth Faltering Children · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05951894 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitas Airlangga
Last refreshed: 21 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05951894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing